Vincent Harlay, Céline Bequet, Romain Appay, Alexandre Bertucci, Gregorio Petrirena, Chantal Campello, Maryline Barrié, Didier Autran, Thomas Graillon, Henry Dufour, Dominique Figarella-Branger, Laetitia Padovani, Anne Barlier, Isabelle Nanni, Emeline Tabouret, Olivier Chinot
{"title":"仅活检不能切除的IDH野生型胶质母细胞瘤患者的自主持续时间。","authors":"Vincent Harlay, Céline Bequet, Romain Appay, Alexandre Bertucci, Gregorio Petrirena, Chantal Campello, Maryline Barrié, Didier Autran, Thomas Graillon, Henry Dufour, Dominique Figarella-Branger, Laetitia Padovani, Anne Barlier, Isabelle Nanni, Emeline Tabouret, Olivier Chinot","doi":"10.1007/s11060-025-05250-3","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>\"Biopsy-only\" glioblastoma (BO-GB) is an understudied entity associated with a poor outcome for whom quality of life preservation is essential. Our objective was to define and determine the time of autonomy duration in BO-GB and its potential predictive factors.</p><p><strong>Methods: </strong>Patients diagnosed with IDH wild-type BO-GB and enrolled in a prospective regional cohort from 2014 to 2017 were analyzed for their clinical features, functional status, histo-molecular profile, neuroimaging findings, and treatment details.</p><p><strong>Results: </strong>137 patients were included in the present analysis. Median age at inclusion was 66 years old and median KPS was 70. Median time of autonomy duration was 7.7 months (CI95%: 5.6-9.7). In the radiotherapy - temozolomide subgroup, median time of autonomy duration was 9.1 months (CI95%: 8.1-10.3); in the chemotherapy upfront group, median time of autonomy duration was 5.3 months (CI95%: 3.5-7.1). Autonomy duration was correlated to patient age and overall survival but not with initial functional status. Among the 65 patients with KPS < 70 at baseline, 11 patients (16.9%) restored their autonomy under treatment. Autonomy duration was not different between these 11 patients and the patients with baseline KPS ≥ 70 (p = 0.758).</p><p><strong>Conclusion: </strong>Autonomy duration may serve as a surrogate endpoint for overall survival for BO-GB patients and may be included in future clinical trials dedicated to this frail population.</p>","PeriodicalId":16425,"journal":{"name":"Journal of Neuro-Oncology","volume":"176 1","pages":"20"},"PeriodicalIF":3.1000,"publicationDate":"2025-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Autonomy duration in patients with biopsy-only unresectable IDH wild-type glioblastomas.\",\"authors\":\"Vincent Harlay, Céline Bequet, Romain Appay, Alexandre Bertucci, Gregorio Petrirena, Chantal Campello, Maryline Barrié, Didier Autran, Thomas Graillon, Henry Dufour, Dominique Figarella-Branger, Laetitia Padovani, Anne Barlier, Isabelle Nanni, Emeline Tabouret, Olivier Chinot\",\"doi\":\"10.1007/s11060-025-05250-3\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>\\\"Biopsy-only\\\" glioblastoma (BO-GB) is an understudied entity associated with a poor outcome for whom quality of life preservation is essential. Our objective was to define and determine the time of autonomy duration in BO-GB and its potential predictive factors.</p><p><strong>Methods: </strong>Patients diagnosed with IDH wild-type BO-GB and enrolled in a prospective regional cohort from 2014 to 2017 were analyzed for their clinical features, functional status, histo-molecular profile, neuroimaging findings, and treatment details.</p><p><strong>Results: </strong>137 patients were included in the present analysis. Median age at inclusion was 66 years old and median KPS was 70. Median time of autonomy duration was 7.7 months (CI95%: 5.6-9.7). In the radiotherapy - temozolomide subgroup, median time of autonomy duration was 9.1 months (CI95%: 8.1-10.3); in the chemotherapy upfront group, median time of autonomy duration was 5.3 months (CI95%: 3.5-7.1). Autonomy duration was correlated to patient age and overall survival but not with initial functional status. Among the 65 patients with KPS < 70 at baseline, 11 patients (16.9%) restored their autonomy under treatment. Autonomy duration was not different between these 11 patients and the patients with baseline KPS ≥ 70 (p = 0.758).</p><p><strong>Conclusion: </strong>Autonomy duration may serve as a surrogate endpoint for overall survival for BO-GB patients and may be included in future clinical trials dedicated to this frail population.</p>\",\"PeriodicalId\":16425,\"journal\":{\"name\":\"Journal of Neuro-Oncology\",\"volume\":\"176 1\",\"pages\":\"20\"},\"PeriodicalIF\":3.1000,\"publicationDate\":\"2025-10-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Neuro-Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s11060-025-05250-3\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Neuro-Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11060-025-05250-3","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
Autonomy duration in patients with biopsy-only unresectable IDH wild-type glioblastomas.
Purpose: "Biopsy-only" glioblastoma (BO-GB) is an understudied entity associated with a poor outcome for whom quality of life preservation is essential. Our objective was to define and determine the time of autonomy duration in BO-GB and its potential predictive factors.
Methods: Patients diagnosed with IDH wild-type BO-GB and enrolled in a prospective regional cohort from 2014 to 2017 were analyzed for their clinical features, functional status, histo-molecular profile, neuroimaging findings, and treatment details.
Results: 137 patients were included in the present analysis. Median age at inclusion was 66 years old and median KPS was 70. Median time of autonomy duration was 7.7 months (CI95%: 5.6-9.7). In the radiotherapy - temozolomide subgroup, median time of autonomy duration was 9.1 months (CI95%: 8.1-10.3); in the chemotherapy upfront group, median time of autonomy duration was 5.3 months (CI95%: 3.5-7.1). Autonomy duration was correlated to patient age and overall survival but not with initial functional status. Among the 65 patients with KPS < 70 at baseline, 11 patients (16.9%) restored their autonomy under treatment. Autonomy duration was not different between these 11 patients and the patients with baseline KPS ≥ 70 (p = 0.758).
Conclusion: Autonomy duration may serve as a surrogate endpoint for overall survival for BO-GB patients and may be included in future clinical trials dedicated to this frail population.
期刊介绍：
The Journal of Neuro-Oncology is a multi-disciplinary journal encompassing basic, applied, and clinical investigations in all research areas as they relate to cancer and the central nervous system. It provides a single forum for communication among neurologists, neurosurgeons, radiotherapists, medical oncologists, neuropathologists, neurodiagnosticians, and laboratory-based oncologists conducting relevant research. The Journal of Neuro-Oncology does not seek to isolate the field, but rather to focus the efforts of many disciplines in one publication through a format which pulls together these diverse interests. More than any other field of oncology, cancer of the central nervous system requires multi-disciplinary approaches. To alleviate having to scan dozens of journals of cell biology, pathology, laboratory and clinical endeavours, JNO is a periodical in which current, high-quality, relevant research in all aspects of neuro-oncology may be found.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
